PARASHLTH

- Audio recording of the Earnings Conference Call held on November 06, 2026, is available on the company's website. - The call covered Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.

- Q2 FY27 Revenue rose 22.8% YoY to ₹510.9 Cr vs ₹416.1 Cr. - Operating EBITDA grew 47.0% YoY to ₹120.2 Cr with margins expanding 390 bps to 23.5%. - PAT surged 3.3x YoY to ₹40.4 Cr from ₹12.4 Cr. - Target set to reach 3,011 beds by 2028.

- Board approved the continuation of Mr. Kabir Kishin Thakur as Non-Executive Non-Independent Director, subject to shareholder approval. - Approved Unaudited Financial Results for the quarter and half-year ended September 30, 2026. - Board meeting was held on November 05, 2026.

- Q2 FY27 Consolidated Revenue increased 22.8% YoY to ₹510.9 Cr. - EBITDA rose 42.5% YoY to ₹126.6 Cr with margins expanding 350 bps to 24.5%. - PAT surged over 3.3x YoY to ₹40.4 Cr. - Deployed ₹375 Cr from IPO proceeds toward debt repayment; bed occupancy reached 73%.

- Paras Healthcare Limited has submitted its financial results for the period ended September 30, 2026 to the Exchange. - Detailed financial tables were not provided in the announcement.